2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…2018 American Transplant Congress
Building a Third-Party VST Bank from Scratch- The Cincinnati Experience
BackgroundViral infections remain a challenge to treat and significantly contribute to morbidity and mortality. Virus specific T cells (VSTs) have shown clinical efficacy, with minimal…2018 American Transplant Congress
Prospective, Multi-Center Observational Study of Cell-Mediated Immunity for Cytomegalovirus Infection in Kidney Transplant Recipients
Background:T-cell-mediated immunity (CMI) is crucial for the control of CMV infection post-transplant. We evaluated a novel EliSpot assay to determine whether CMI results could predict…2017 American Transplant Congress
Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study.
Hepatitis E virus (HEV) is responsible for acute and chronic autochthonous hepatitis in developed countries, particularly in Western Europe. Conversely to hepatitis B or C,…2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…2017 American Transplant Congress
Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.
1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora
Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…2017 American Transplant Congress
Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.
Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…2017 American Transplant Congress
Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs.
Cytomegalovirus (CMV) infection is a major cause of morbidity, mortality, and shortened graft survival in kidney transplant recipients. Efforts to prevent CMV infection have traditionally…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 14
- Next Page »